
### [NCIT:C8124](http://purl.obolibrary.org/obo/NCIT_C8124)
**Label:** Stage II Adult Immunoblastic Lymphoma

**Subclasses:** 

**Class expressions from DL-Learner:**

- Thing 54.80%
- [NCIT:C28054](http://purl.obolibrary.org/obo/NCIT_C28054) (Stage II) 51.39%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39897](http://purl.obolibrary.org/obo/NCIT_C39897) (Prostate Ductal Adenocarcinoma, Solid Pattern))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39896](http://purl.obolibrary.org/obo/NCIT_C39896) (Prostate Ductal Adenocarcinoma, Papillary Pattern))) 36.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39895](http://purl.obolibrary.org/obo/NCIT_C39895) (Prostate Ductal Adenocarcinoma, Cribriform Pattern))) 36.74%


